ライフサイエンスコーパス: atypical antipsychotic

1 tients who had just discontinued a different atypical antipsychotic.

2 re effective than switching to another newer atypical antipsychotic.

3 receiving a concurrent mood stabilizer or an atypical antipsychotic.

4 ttings, some clinical symptoms improved with atypical antipsychotics.

5 predictor of response time to two first-line atypical antipsychotics.

6 l rates were 50.1% for typical and 54.9% for atypical antipsychotics.

7 as of the brain implicated in the actions of atypical antipsychotics.

8 e was some evidence for superior efficacy of atypical antipsychotics.

9 t 5-HT2A leads to a novel approach to potent atypical antipsychotics.

10 rt because of the escalating prescription of atypical antipsychotics.

11 finding to structurally diverse typical and atypical antipsychotics.

12 e of response, even when compared with other atypical antipsychotics.

13 uent in individuals taking conventional than atypical antipsychotics.

14 ne receptor antagonists, such as typical and atypical antipsychotics.

15 e efficacious when given in combination with atypical antipsychotics.

16 of action for the metabolic dysregulation of atypical antipsychotics.

17 ration of antipsychotic drugs, the so-called atypical antipsychotics.

18 The potential atypical antipsychotic 5bb was selected for further phar

19 Atypical antipsychotic (AAP) medications that have revol

20 ent of schizophrenia spectrum disorders with atypical antipsychotics (AAPs), there is still need for

21 d in vivo activities indicative of potential atypical antipsychotic activity, anthranilamide 77 (1192

22 rmacological profile indicative of potential atypical antipsychotic activity.

23 SD duration of treatment with the identified atypical antipsychotic agent was 68.3 +/- 28.9 months (c

24 Quetiapine is an atypical antipsychotic agent with a complex pharmacology

25 to the superior therapeutic effects of this atypical antipsychotic agent.

26 It meets several of the criteria for a novel atypical antipsychotic agent.

27 ly in phase I clinical trials as a potential atypical antipsychotic agent.

28 y was investigated as an approach to a novel atypical antipsychotic agent.

29 ia, and changes in response to the advent of atypical antipsychotic agents can be understood in the c

30 However, data on the safety and efficacy of atypical antipsychotic agents in children are limited.

31 the efficacy and tolerability of adjunctive atypical antipsychotic agents in major depressive disord

32 should utilize omega-3, anticonvulsants, and atypical antipsychotic agents in treating specific DSM-5

33 Manufacturers of atypical antipsychotic agents without online registries

34 However, atypical antipsychotic agents, in combination with the n

35 ents with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whethe

36 osure to modern psychotropic agents, such as atypical antipsychotic agents, selective serotonin reupt

37 Atypical antipsychotic agents, which block postsynaptic

38 ess the effect of race on the use of various atypical antipsychotic agents.

39 ives was prepared and evaluated as potential atypical antipsychotic agents.

40 Chronic use of atypical antipsychotics also was associated with decreas

41 Clozapine represents the best-characterized atypical antipsychotic, although it displays only modera

42 that the BN rat may be useful for detecting atypical antipsychotics and antipsychotics with novel me

43 lignant syndrome can occur in patients given atypical antipsychotics and resembles "classical" neurol

44 A protective association between the use of atypical antipsychotics and risk of clinically significa

45 ion status (highest in patients treated with atypical antipsychotics), and smoking (higher in smokers

46 ons for conventional antipsychotics, 37% for atypical antipsychotics, and 23% for both atypical and c

47 ha-adrenergic agents, other antidepressants, atypical antipsychotics, and antiepileptic agents.

48 se of treatment alternatives (psychotherapy, atypical antipsychotics, and anxiolytics).

49 difications induced at the mGlu2 promoter by atypical antipsychotics, and augmented their therapeutic

50 ic agents, anticonvulsants, benzodiazepines, atypical antipsychotics, and novel agents.

51 We have previously shown that atypical antipsychotics antagonize DA D2 receptor (D2R)/

52 Medications included were antidepressants, atypical antipsychotics, anticonvulsants, lithium, and o

53 of commonly prescribed medications including atypical antipsychotics, antidepressants, and anxiolytic

54 scription patterns for these medications, an atypical antipsychotic approved in 1989, and conventiona

55 Atypical antipsychotics are effective augmentation agent

56 ssing the human disease gene, identified the atypical antipsychotic aripiprazole as one of the hits.

57 upropion group, n = 506); or augment with an atypical antipsychotic, aripiprazole (augment-aripiprazo

58 Use of atypical antipsychotics as a group increased during the

59 ratios were 23.2% for typical and 14.1% for atypical antipsychotics at 12 months; thus, patients who

60 Use of atypical antipsychotics began to decline significantly i

61 er of influence were hypertension, use of an atypical antipsychotic, bipolar diagnosis, and older age

62 was improved by clozapine, the prototypical atypical antipsychotic, but not by haloperidol, a typica

63 Data on treatment efficacy are strongest for atypical antipsychotics, but these agents must be used w

64 respondents, with lorazepam by 12%, and with atypical antipsychotics by <5%.

65 safety, and tolerability of cariprazine, an atypical antipsychotic candidate, in adult patients with

66 antipsychotic haloperidol (1 mg/kg) and the atypical antipsychotic clozapine (20 mg/kg) increased BD

67 f c-Fos immunoreactivity comparable with the atypical antipsychotic clozapine and enhanced prepulse i

68 hermore, we assessed the extent to which the atypical antipsychotic clozapine and the typical antipsy

69 n network activity because L-745,870 and the atypical antipsychotic clozapine dramatically reduce the

70 ical effects of glycine as an adjunct to the atypical antipsychotic clozapine in the treatment of sch

71 t in the early 1990s when studies showed the atypical antipsychotic clozapine possessed higher affini

72 r blockers carvedilol and labetalol, and the atypical antipsychotic clozapine, in reversing MDMA-indu

73 c (mGlu) receptor agonist LY379268, like the atypical antipsychotic clozapine, increased extracellula

74 rs compared the efficacy and safety of three atypical antipsychotics (clozapine, olanzapine, and risp

75 who prospectively failed to improve with an atypical antipsychotic, clozapine was more effective tha

76 y in a dose-dependent manner, similar to the atypical antipsychotic, clozapine.

77 bral cortex of mice after treatment with the atypical antipsychotic, clozapine.

78 evaluate adverse effects and tolerability of atypical antipsychotics compared with first-generation a

79 gic exposures and fatalities associated with atypical antipsychotics continue to increase in the Unit

80 drugs do not improve this deficit while some atypical antipsychotics do.

81 Here we found that chronic atypical antipsychotics downregulated the transcription

82 ve 5-HT2A receptor antagonist and a putative atypical antipsychotic drug (APD), markedly potentiates

83 ma Co. Ltd., Tokyo, Japan), a newly approved atypical antipsychotic drug (APD), on NMDAR synaptic fun

84 udy investigated the effects of the putative atypical antipsychotic drug (APD), risperidone, on stria

85 derstanding the complex neural mechanisms of atypical antipsychotic drug action.

86 he D site, risperidone and not the prototype atypical antipsychotic drug clozapine increased the freq

87 ional antipsychotic drug haloperidol and the atypical antipsychotic drug clozapine mediate gene expre

88 imbic cortices, resembling the action of the atypical antipsychotic drug clozapine.

89 nction; the deficits were ameliorated by the atypical antipsychotic drug clozapine.

90 an analog of neurotensin(8-13), acts like an atypical antipsychotic drug in several dopamine-based an

91 significantly potentiated the effects of the atypical antipsychotic drug risperidone (0.1 mg/kg) on D

92 The atypical antipsychotic drug risperidone, a multireceptor

93 Atypical antipsychotic drug treatment is clinically effe

94 Atypical antipsychotic drug use is associated with an in

95 Atypical antipsychotic drug use versus nonuse was associ

96 Amisulpride is an atypical antipsychotic drug with selective affinity for

97 Chronic administration of the atypical antipsychotic drug, clozapine, to rodents has b

98 imilar to previous results obtained with the atypical antipsychotic drug, clozapine.

99 performed a long-term comparison of a newer, atypical antipsychotic drug, risperidone, and an older,

100 e responsive to treatment with clozapine, an atypical antipsychotic drug.

101 ts who were being treated with clozapine, an atypical antipsychotic drug.

102 The atypical antipsychotic drugs (AAPDs) have markedly enhan

103 Atypical antipsychotic drugs (APDs) have been hypothesiz

104 The main class of atypical antipsychotic drugs (APDs) in current use inclu

105 Atypical antipsychotic drugs (APDs) such as clozapine, b

106 en suggested to contribute to the ability of atypical antipsychotic drugs (APDs), e.g. clozapine, ris

107 , e.g., valproic acid and carbamazepine, and atypical antipsychotic drugs (APDs), e.g., clozapine, qu

108 Acute treatment with atypical antipsychotic drugs (APDs), which are serotonin

109 e a paradigm shift due to development of new atypical antipsychotic drugs (APDs), with better tolerab

110 SZ; and 3) NC and SZ treated with typical or atypical antipsychotic drugs (APDs).

111 ion of 29,952 recipients of conventional and atypical antipsychotic drugs aged younger than 60 years,

112 The incidence-rate ratio for users of atypical antipsychotic drugs as compared with users of t

113 n mediating the actions of hallucinogens and atypical antipsychotic drugs at 5-HT(2A) and 5-HT(2C) se

114 ly innervated with 5-HT2A receptors to which atypical antipsychotic drugs bind with high affinity, li

115 veloped because there are no rapid-acting IM atypical antipsychotic drugs currently available in the

116 effects offset advantages in the efficacy of atypical antipsychotic drugs for the treatment of psycho

117 Current users of typical and of atypical antipsychotic drugs had a similar, dose-related

118 Current users of typical and of atypical antipsychotic drugs had higher rates of sudden

119 We assessed the effectiveness of atypical antipsychotic drugs in outpatients with Alzheim

120 he cytotoxicity of both the conventional and atypical antipsychotic drugs in relation to their effect

121 drugs, and there may be differences between atypical antipsychotic drugs in their patterns of cognit

122 Because atypical antipsychotic drugs increase dopamine (DA) and

123 fluid concentrations of the peptide and (ii) atypical antipsychotic drugs may exert their therapeutic

124 Recent evidence suggests that some atypical antipsychotic drugs may protect against oxidati

125 Patients receiving atypical antipsychotic drugs showed unimpaired visual co

126 Some atypical antipsychotic drugs were identified by their hi

127 Atypical antipsychotic drugs, by definition, differ from

128 bens, whereas treatment for 21 days with the atypical antipsychotic drugs, clozapine or olanzapine, i

129 It is a putative therapeutic target of atypical antipsychotic drugs, notably clozapine, as well

130 Haloperidol and clozapine, typical and atypical antipsychotic drugs, respectively, were then te

131 Several adverse outcomes attributed to atypical antipsychotic drugs, specifically quetiapine, r

132 striatum and the nucleus accumbens, whereas atypical antipsychotic drugs, such as clozapine and olan

133 Atypical antipsychotic drugs, such as clozapine and risp

134 receptor (5-HT2AR) is a prominent target for atypical antipsychotic drugs, such as clozapine.

135 s respond to the action of hallucinogens and atypical antipsychotic drugs, we have examined the cellu

136 is known regarding the cardiac safety of the atypical antipsychotic drugs, which have largely replace

137 cy and low extrapyramidal symptom profile of atypical antipsychotic drugs, without the need for 5-HT(

138 y was designed to examine the effects of the atypical antipsychotic drugs--risperidone, clozapine and

139 any therapeutic drugs, including typical and atypical antipsychotic drugs.

140 D(2)/D(3) receptor blockade to that of other atypical antipsychotic drugs.

141 cular targets for LSD-like hallucinogens and atypical antipsychotic drugs.

142 s an important target for antidepressant and atypical antipsychotic drugs.

143 roposed site of action of hallucinogenic and atypical antipsychotic drugs.

144 e levels) within 90 days of prescription for atypical antipsychotic drugs.

145 ween the actions of prototypical typical and atypical antipsychotic drugs.

146 rs in subjects being treated with typical or atypical antipsychotic drugs.

147 fferential behavioral effects of typical and atypical antipsychotic drugs.

148 schizophrenia patients receiving typical and atypical antipsychotic drugs; a two-alternative, forced-

149 he relative effect of the second-generation (atypical) antipsychotic drugs and older agents on neuroc

150 Second-generation (atypical) antipsychotic drugs are widely used to treat p

151 relative effectiveness of second-generation (atypical) antipsychotic drugs as compared with that of o

152 risk-benefit treatment decisions about using atypical antipsychotics during pregnancy.

153 Second-generation, or atypical, antipsychotics effectively treat psychiatric i

154 observation consistent with a prediction for atypical antipsychotic efficacy.

155 sents a valuable lead for the development of atypical antipsychotics endowed with a unique pharmacolo

156 Use of atypical antipsychotics for neuropsychiatric symptoms of

157 suggest that there is no clear evidence that atypical antipsychotics generate cost savings or are cos

158 tylase (HDAC) inhibitor valproate (VPA) with atypical antipsychotics has become a frequent treatment

159 lycemia and hypercholesterolemia with use of atypical antipsychotics has been documented in case repo

160 While the atypical antipsychotics have a 'black box warning' on ri

161 Atypical antipsychotics have become indispensable in the

162 ion warnings in the past year about how some atypical antipsychotics have been marketed to minimize t

163 Typical and atypical antipsychotics have been shown to alleviate N-m

164 hereas its metabolite paliperidone and other atypical antipsychotics have similar potencies for the t

165 dely prescribed pharmacological treatments - atypical antipsychotics - have a modest but significant

166 The risk was increased for use restricted to atypical antipsychotics (HR = 2.89 [95% CI = 1.64-5.10])

167 ching to clozapine with switching to another atypical antipsychotic in patients who had discontinued

168 who had discontinued treatment with a newer atypical antipsychotic in the context of the Clinical An

169 d and Drug Administration warned that use of atypical antipsychotics in dementia was associated with

170 nds are added to both conventional and newer atypical antipsychotics in efficacy models although an e

171 l data exist on possible differences between atypical antipsychotics in efficacy, overall tolerabilit

172 The effects of atypical antipsychotics in this population were statisti

173 dings suggest a role for olanzapine or other atypical antipsychotics in treating SSRI-resistant PTSD.

174 reviewed: benzodiazepines, neuroleptics, and atypical antipsychotics, including side effects, dosages

175 7, the odds of receipt of a prescription for atypical antipsychotics increased for African Americans

176 trends in pharmacotherapy include the use of atypical antipsychotics instead of the classic antipsych

177 Before an atypical antipsychotic is started, a comprehensive asses

178 attributable risk of diabetes mellitus with atypical antipsychotics is small.

179 ovel neurotensin (8-13) analog that produces atypical antipsychotic-like effects in animal models.

180 ance response (CAR) assay, BuTAC exhibits an atypical antipsychotic-like profile by selectively decre

181 efficacy and safety of the first long-acting atypical antipsychotic (long-acting injectable risperido

182 cal interventions using mood stabilizers and atypical antipsychotics may be effective for some sympto

183 neuroleptic malignant syndrome criteria, and atypical antipsychotics may cause neurotoxicities unrela

184 Current atypical antipsychotics may offer neurological and cogni

185 optimizing antipsychotic treatment and that atypical antipsychotics may prove to be most effective.

186 associations between NF-L and treatment with atypical antipsychotics, MBP and lamotrigine, and H-FABP

187 ith first-episode schizophrenia who received atypical antipsychotics (medicated patient group) (n = 2

188 Controlled trials comparing an atypical antipsychotic medication (risperidone, olanzapi

189 Random-effects analysis revealed that in atypical antipsychotic medication arms, the degree of im

190 ia and who began receiving a conventional or atypical antipsychotic medication between 1994 and 2003.

191 determine striatal blood flow during active atypical antipsychotic medication treatment and after at

192 done, or paliperidone) with placebo, another atypical antipsychotic medication, or other pharmacother

193 Atypical antipsychotic medications (second-generation an

194 Atypical antipsychotic medications are commonly used for

195 Atypical antipsychotic medications are indicated for the

196 Atypical antipsychotic medications are widely prescribed

197 ntly higher adjusted risk of death than were atypical antipsychotic medications at all intervals stud

198 etermine the benefits vs risks of continuing atypical antipsychotic medications beyond 12 weeks.

199 Numbers of prescriptions of anxiolytic and atypical antipsychotic medications did not significantly

200 pared the efficacy and safety of typical and atypical antipsychotic medications directly in patients

201 Benefits and harms vary among atypical antipsychotic medications for off-label use.

202 Atypical antipsychotic medications for the adjunctive tr

203 d and Drug Administration approved three new atypical antipsychotic medications for the treatment of

204 patients with schizophrenia who were taking atypical antipsychotic medications had bilateral thalami

205 The patients receiving atypical antipsychotic medications had normal-range P50

206 Atypical antipsychotic medications have generally been f

207 rt the hypothesis that patients treated with atypical antipsychotic medications have normal P50 measu

208 There are limited data regarding the use of atypical antipsychotic medications in pregnancy.

209 ration (FDA) issued an advisory stating that atypical antipsychotic medications increase mortality am

210 While new atypical antipsychotic medications may have a safer ther

211 Atypical antipsychotic medications may have superior cli

212 rtant, therefore, to evaluate the effects of atypical antipsychotic medications on measures such as P

213 ssociated with conventional as compared with atypical antipsychotic medications persisted in confirma

214 eview of the efficacy and safety profiles of atypical antipsychotic medications used for the adjuncti

215 e, olanzapine, or risperidone (classified as atypical antipsychotic medications) was compared to that

216 Despite the widespread use of atypical antipsychotic medications, alarmingly high rate

217 major site of action of clozapine and other atypical antipsychotic medications, are, paradoxically,

218 ain is a commonly observed adverse effect of atypical antipsychotic medications, but associated chang

219 these molecules mediated by both typical and atypical antipsychotic medications.

220 outpatient veterans receiving typical versus atypical antipsychotic medications.

221 are warranted even for patients who receive atypical antipsychotic medications.

222 enia were tested without and with typical or atypical antipsychotic medications: no differences could

223 e treated with risperidone and paliperidone, atypical antipsychotic medications; fluoxetine, a select

224 =49) or blinded treatment with another newer atypical antipsychotic not previously received in the tr

225 Beginning on P62, rats were administered the atypical antipsychotic olanzapine (2.5 mg/kg) twice dail

226 The impact of the atypical antipsychotics olanzapine, quetiapine, and risp

227 As a group, the atypical antipsychotics (olanzapine, quetiapine, and ris

228 ntipsychotic, haloperidol (2-20 mg/d), or an atypical antipsychotic, olanzapine (5-20 mg/d).

229 The present study addresses whether another atypical antipsychotic, olanzapine, will also improve se

230 ned to compare the therapeutic profile of an atypical antipsychotic, olanzapine, with that of a conve

231 o a typical antipsychotic, haloperidol or an atypical antipsychotic, olanzapine.

232 The study measured the effects of atypical antipsychotics on psychiatric and behavioral sy

233 observational study of women treated with an atypical antipsychotic or haloperidol during pregnancy.

234 trials with random assignment to adjunctive atypical antipsychotic or placebo.

235 ncreases in psychotherapy or prescription of atypical antipsychotics or anxiolytics.

236 the adjusted relative odds of receipt of an atypical antipsychotic prescription for African American

237 ssociation of ethnic group and receipt of an atypical antipsychotic prescription over time, adjusted

238 32 visits; 33% of overall visits involved an atypical antipsychotic prescription.

239 rly gaps between ethnic groups in receipt of atypical antipsychotic prescriptions decreased throughou

240 cells in the ventral striatum confirmed the atypical antipsychotic profile of 5bb in agreement with

241 The atypical antipsychotic quetiapine was used to reverse PP

242 hizophrenia (N=444) who had discontinued the atypical antipsychotic randomly assigned during phase 1

243 e needed to determine whether treatment with atypical antipsychotics results in superior outcomes for

244 J McCracken and colleagues showed that the atypical antipsychotic risperidone reduced serious behav

245 s and patient populations and with the other atypical antipsychotics (risperidone, olanzapine, and qu

246 who had just discontinued treatment with an atypical antipsychotic, risperidone and olanzapine were

247 e antipsychotic medication, particularly the atypical antipsychotic, risperidone.

248 toms are typical antipsychotic resistant and atypical antipsychotic sensitive indicate that other sys

249 Second-generation (atypical) antipsychotics (SGAs) are more expensive than

250 lt in APDs with improved therapeutic profile.Atypical antipsychotics show reduced extrapyramidal side

251 Typical antipsychotic and atypical antipsychotic subjects do have differing patter

252 Atypical antipsychotics such as olanzapine often induce

253 To date all typical and atypical antipsychotics target the dopamine D(2) recepto

254 e moderately higher in patients who received atypical antipsychotics than in those who received typic

255 ment is an additional risk of treatment with atypical antipsychotics that should be considered when t

256 art of an efficacy and tolerability study of atypical antipsychotics, the authors used a performance-

257 as there are no trials in children comparing atypical antipsychotics, the mainstay of current treatme

258 positive symptoms, and maintained on stable atypical antipsychotic therapy underwent a 3-week screen

259 patients diagnosed with Schizophrenia taking Atypical Antipsychotics to Depressive patients medicated

260 n of startle magnitude, may be improved with atypical antipsychotic treatment.

261 ve in decreasing weight gain associated with atypical antipsychotic use and is well tolerated by chil

262 to determine the effects of conventional and atypical antipsychotic use on time to nursing home admis

263 Clozapine, an atypical antipsychotic used in the treatment of refracto

264 The adjusted rate ratio for current users of atypical antipsychotics was 0.84 (95% confidence interva

265 The National Pregnancy Registry for Atypical Antipsychotics was established to determine the

266 Overall use of atypical antipsychotics was slightly less common for Afr

267 pecified for psychotic disorders, receipt of atypical antipsychotics was still lower for African Amer

268 e-induced dermatologic outcome and MC4R with atypical antipsychotic weight gain.

269 time to death, but neither conventional nor atypical antipsychotics were associated with time to dea

270 In CATIE-AD, atypical antipsychotics were associated with worsening c

271 atients with schizophrenia on chronic stable atypical antipsychotics were randomized to encenicline 0

272 Adjunctive atypical antipsychotics were significantly more effectiv

273 e risks of diabetes mellitus associated with atypical antipsychotics were small, ranging from 0.05% (

274 Olanzapine (OLZ) is an atypical antipsychotic whose clinical efficacy is hamper

275 g at different drugs, particularly the newer atypical antipsychotics, will be reviewed.

276 f a dopaminergic agonist (apomorphine) or an atypical antipsychotic with mixed dopamine/serotonin ant

277 he potential pharmacological alternatives to atypical antipsychotics with the most encouraging prelim

278 Benefits elicited by a combination of atypical antipsychotics with valproate (VPA) (a histone

279 risks and claiming superior safety to other atypical antipsychotics without adequate substantiation,